Oncology

Latest News

Insurance gaps | Image Credit: iQoncept-stock.adobe.com
Insurance Gaps Threaten Cancer Treatment Success

July 7th 2025

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com
Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

June 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 8th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 8th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says
December 31st 2017

Smokers Willing to Try E-Cigarettes More Successful at Smoking Less, Study Says

Allison Inserro
A small pilot study from the Hollings Cancer Center at the Medical University of South Carolina found that smokers who are willing to use e-cigarettes tend to smoke less and have increased quit attempts.
Site Logo
December 29th 2017

The Impact High OOP Costs Have on Patients Filling Prescriptions for Oral Cancer Drugs

Laura Joszt, MA
Patients with cancer may have more options for oral cancer medications, but high out-of-pocket costs still present a barrier to access, according to a new study in Journal of Clinical Oncology.
This Week in Managed Care: December 29, 2017
December 29th 2017

This Week in Managed Care: December 29, 2017

This week, the top managed care stories included a road map to develop state-level programs to care for complex populations; the Physician-focused Payment Technical Advisory Committee backed 2 new alternative payment models; a new cancer gene profiling test may open doors to new targeted therapies.
Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM
December 29th 2017

Top 2017 Articles in AJMC®'s Evidence-Based OncologyTM

Surabhi Dangi-Garimella, PhD
A look at the most popular articles published in Evidence-Based Oncology™ in 2017.
Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation
December 27th 2017

Dr Amy Abernethy Discusses Community Oncologists' Role in Modernizing Evidence Generation

Community oncologists have a major role in accelerating treatment development and providing them to patients, said Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies
December 27th 2017

Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies

Jaime Rosenberg
While FoundationOne CDx, the comprehensive companion diagnostic test for solid tumors, gives patients the ability to be accurately matched with a targeted therapy, it also has potential benefits for patients with a less common types of cancers, said Stuart Goldberg, MD, chief scientific officer, Cota, in an interview with The American Journal of Managed Care®.
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26th 2017

Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate

Until more data is available, it’s difficult for a practice or physician group to make an accurate assessment of whether or not 2-sided risk is appropriate, said Sarah Cevallos, chief revenue cycle officer, Florida Cancer Specialists. Physicians would need to see clear metrics in order to know if they will be achievable.
The Role of Oncologists in Moving to Value-Based Care: Torrie Fields Interviews Dr Michael Kolodziej
December 25th 2017

The Role of Oncologists in Moving to Value-Based Care: Torrie Fields Interviews Dr Michael Kolodziej

In this interview, recorded at the end of the first day of PCOC®, Torrie Fields, senior program manager at Blue Shield of California, and Michael Kolodziej, MD, of ADVI Health, discuss the move to value-based care in oncology, what practices need to do to be successful, and the role of team-based care.
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25th 2017

Dr Shannon Maude Discusses Side Effects of CAR T Therapies

Most primary side effects of CAR T therapies occur early on after treatment and resolve quickly, but there are some that require long-term monitoring, explained Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Podcast: This Week in Managed Care—Individual Mandate Eliminated and Other Health News
December 23rd 2017

Podcast: This Week in Managed Care—Individual Mandate Eliminated and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Dr Bobby Green on How Flatiron Is Working to Improve Care Delivery
December 23rd 2017

Dr Bobby Green on How Flatiron Is Working to Improve Care Delivery

Bobby Green, MD, MSCE, senior vice president of clinical oncology at Flatiron Health, discusses analyzing patient data to improve the overall care delivery and its challenges involved with being so early in the process.
This Week in Managed Care: December 22, 2017
December 22nd 2017

This Week in Managed Care: December 22, 2017

This week, the top managed care stories included the elimination of the Affordable Care Act's individual mandate; a new gene therapy for inherited vision loss that could cost $1 million; and a study found that social isolation can increase the risk of type 2 diabetes.
Site Logo
December 22nd 2017

Medical World News®, December 2017

AJMC Staff
Key drug approvals; alcohol cancer link.
Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017
December 22nd 2017

Articles That Gained the Most Traction on Facebook, Twitter, and LinkedIn in 2017

Jaime Rosenberg
Articles on type 2 diabetes management, colon cancer screenings, and anti-rheumatic drug approvals topped the list.
Terrill Jordan: Year 1 Feedback on OCM
December 22nd 2017

Terrill Jordan: Year 1 Feedback on OCM

Based on CMMI's year 1 feedback on OCM, it is clear that a lot of planning is needed and education is crucial, said Terrill Jordan, CEO, of Regional Cancer Care Associates.
5 Aspects of How Diet Does, and Does Not, Impact Health
December 22nd 2017

5 Aspects of How Diet Does, and Does Not, Impact Health

Laura Joszt, MA
For the most part, it’s well known that eating healthy and in moderation is more beneficial to our health. In 2017, there were a number of news stories that drove that knowledge home.
FDA Grants Approval to Pertuzumab for Adjuvant Treatment in Patients With HER2-Positive Breast Cancer
December 21st 2017

FDA Grants Approval to Pertuzumab for Adjuvant Treatment in Patients With HER2-Positive Breast Cancer

Jaime Rosenberg
The FDA's 2013 accelerated approval of pertuzumab for neoadjuvant use was converted to full approval as part of treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer.
Site Logo
December 20th 2017

Will 2-Sided Risk Be a Reality in the OCM?

Kelly Davio
Site Logo
December 20th 2017

AJMC®tv Interviews, December 2017

The Center for Biosimilars&reg Laura Joszt, MA
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Insights From Top 5 AJMC.com Contributor Articles of 2017
December 20th 2017

Insights From Top 5 AJMC.com Contributor Articles of 2017

Allison Inserro
Contributors to AJMC.com delved into data to share their knowledge about important topics in managed care, and in 2017, these were the top 5 most-read articles they wrote and published on our online managed care network.
Nat Turner on Using Data for New Payment Model Requirements
December 20th 2017

Nat Turner on Using Data for New Payment Model Requirements

Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.
Site Logo
December 20th 2017

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

Stanley E. Waintraub, MD Donna McNamara, MD Deena Mary Atieh Graham, MD Andrew L. Pecora, MD John Min, BS Tommy Wu, BA Hyun Gi Noh, MSC Jacqueline Connors, RN, OCN Ruth Pe Benito, MPH, BS Kelly Choi, MD Eric Schultz, BS Stuart L. Goldberg, MD
Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.
Site Logo
December 19th 2017

High-Impact Workflow Changes for Value-Based Care Success

Charles Saunders, MD Charles Alcorn, MS Catherine Cowan, MSN, RN Maria Fabbiano
As oncology practices transition to value-based care, they are challenged to take on more holistic responsibility for their patient. Fortunately, the examples of practices participating in CMS’ Oncology Care Model can offer valuable insight into the most impactful workflow changes providers can implement as they strive to achieve cost and quality improvements.
Site Logo
December 19th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD
Coverage from the Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24 in Tysons Corner, Virginia.
Site Logo
December 19th 2017

How Has the OCM Evolved? Year 1 Provider Updates

Surabhi Dangi-Garimella, PhD
Site Logo
December 19th 2017

Stakeholders Weigh in on Payment Reform in Cancer Care

Surabhi Dangi-Garimella, PhD
Coverage from the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform, held October 23-24 in Tysons Corner, Virginia.
Increased CD8+ TIL Counts Linked to Prolonged Survival in Patients With Certain Ovarian Cancers
December 19th 2017

Increased CD8+ TIL Counts Linked to Prolonged Survival in Patients With Certain Ovarian Cancers

Jaime Rosenberg
Increasing levels of CD8+ tumor-infiltrating lymphocytes are associated with prolonged survival in patients with high-grade serous ovarian cancer, endometrioid ovarian cancer, and mucinous ovarian cancer, according to a study published in JAMA Oncology.
Tesh Khullar on the Importance of Community Oncology Patients Being Involved in Clinical Trials
December 19th 2017

Tesh Khullar on the Importance of Community Oncology Patients Being Involved in Clinical Trials

Community oncologists face a challenge in getting patients into clinical trials, but new technology could help them get access to those trials, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 19th 2017

New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017

Laura Joszt, MA
The FDA was busy in 2017, with a number of notable approvals, including the first chimeric antigen receptor T-cell treatment. In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, employees from the FDA presented data on 5 new drug approvals in leukemia and lymphoma in 2017.
Sarcopenia and Inflammation Associated With Increased Risk of Death in Patients with Colorectal Cancer
December 19th 2017

Sarcopenia and Inflammation Associated With Increased Risk of Death in Patients with Colorectal Cancer

Jaime Rosenberg
A study published in JAMA Oncology found that prediagnosis inflammation was associated with at-diagnosis sarcopenia, and the combination of the 2 nearly doubled the risk of death in patients with nonmetastatic colorectal cancer. Because the 2 biomarkers are commonly collected and potentially modifiable, there is potential for clinical use in prognostication and guiding intervention.
<1
...
606162636465666768
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo